Ligand Pharmaceuticals Incorporated
US ˙ NasdaqGM ˙ US53220K5048

SecurityLGND / Ligand Pharmaceuticals Incorporated
InstitutionFmr Llc
Latest Disclosed Ownership486,071 shares
Ownership 2.33%
Fmr Llc ownership in LGND / Ligand Pharmaceuticals Incorporated

2017-02-14 - Fmr Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 486,071 shares of Ligand Pharmaceuticals Incorporated (US:LGND). This represents 2.325 percent ownership of the company. In their previous filing dated 2016-02-12 , Fmr Llc had reported owning 1,110,624 shares, indicating a decrease of -56.23 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2017-02-14 2017-02-14 13G/A 1,110,624 486,071 -56.23 2.33 -58.28
2016-02-12 2016-02-12 13G 1,110,624 5.57
2015-02-13 2015-02-13 13G/A 949,668 4.74
2014-02-14 2014-02-14 13G 1,664,786 8.16

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 596,127 16,972 2.93 119,017 8.69 0.0012
2026-02-17 2025-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 579,155 121,924 26.67 109,501 35.20 0.0056
2025-11-13 2025-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 457,231 431,008 1,643.63 80,994 2,617.89 0.0042
2025-08-14 2025-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 26,223 1,290 5.17 2,981 13.70 0.0002
2025-05-12 2025-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 24,933 6,102 32.40 2,621 29.95 0.0002
2025-02-13 2024-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 18,831 6,082 47.71 2,018 58.07 0.0001
2024-11-13 2024-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 12,749 10,789 550.46 1,276 673.33 0.0001
2024-08-13 2024-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,960 152 8.41 165 25.00 0.0000
2024-05-13 2024-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,808 -8,185 -81.91 132 -81.49 0.0000
2024-02-13 2023-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 9,993 9,655 2,856.51 714 3,465.00 0.0001
2023-11-13 2023-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 338 -221 -39.53 20 -50.00 0.0000
2023-08-11 2023-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 559 -7 -1.24 40 -2.44 0.0000
2023-08-11 2023-03-31 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 566 156 38.05 42 51.85 0.0000
2023-05-11 2023-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 566 156 42 0.0000
2023-02-13 2022-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 410 -398 -49.26 27 -61.43 0.0000
2022-11-10 2022-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 808 32 4.12 70 1.45 0.0000
2022-08-12 2022-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 776 -428 -35.55 69 -48.89 0.0000
2022-05-13 2022-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,204 785 187.35 135 110.94 0.0000
2022-02-14 2021-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 419 -4 -0.95 64 8.47 0.0000
2022-02-14 2021-09-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 423 -702 -62.40 59 -60.14 0.0000
2021-11-15 2021-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 423 -702 59 0.0000
2021-08-13 2021-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,125 15 1.35 148 -12.43 0.0000
2021-05-14 2021-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,110 206 22.79 169 87.78 0.0000
2021-02-08 2020-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 904 -209 -18.78 90 -15.89 0.0000
2020-11-13 2020-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,113 -3,109 -73.64 107 -77.33 0.0000
2020-08-24 2020-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 4,222 -7,233 -63.14 472 -43.27 0.0001
2020-08-13 2020-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 4,222 -7,233 472 11.5957
2020-05-14 2020-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 11,455 -45,659 -79.94 832 -86.03 0.0001
2020-02-07 2019-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 57,114 -8,517 -12.98 5,957 -8.82 0.0007
2019-11-13 2019-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 65,631 -61,671 -48.44 6,533 -55.04 0.0008
2019-08-13 2019-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 127,302 -152,203 -54.45 14,532 -58.64 0.0017
2019-05-13 2019-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 279,505 -59,439 -17.54 35,136 -23.61 0.0042
2019-02-13 2018-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 338,944 -197,688 -36.84 45,994 -68.78 0.0063
2018-11-09 2018-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 536,632 96,048 21.80 147,300 61.38 0.0166
2018-08-10 2018-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 440,584 14,017 3.29 91,276 29.56 0.0108
2018-05-14 2018-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 426,567 -3,317 -0.77 70,452 19.69 0.0084
2018-02-12 2017-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 429,884 -102,201 -19.21 58,864 -18.74 0.0069
2017-11-13 2017-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 532,085 130,872 32.62 72,443 48.73 0.0088
2017-08-29 2017-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 401,213 -22,850 -5.39 48,707 8.52 0.0061
2017-08-11 2017-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 401,213 -22,850 48,707
2017-05-11 2017-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 424,063 -62,000 -12.76 44,883 -9.12 0.0057
2017-02-10 2016-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 486,063 -474,000 -49.37 49,389 -49.59 0.0066
2016-11-14 2016-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 960,063 -95,400 -9.04 97,984 -22.16 0.0130
2016-08-11 2016-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,055,463 80,200 8.22 125,885 20.53 0.0172
2016-05-16 2016-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 975,263 -135,300 -12.18 104,441 -13.26 0.0144
2016-02-12 2015-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,110,563 70,701 6.80 120,407 35.19 0.0162
2015-11-10 2015-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,039,862 20,630 2.02 89,064 -13.40 0.0127
2015-08-25 2015-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 1,019,232 3,940 0.39 102,841 31.36 0.0132
2015-08-13 2015-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,019,232 102,841
2015-05-14 2015-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,015,292 65,624 6.91 78,289 54.93 0.0100
2015-02-17 2014-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 949,668 -464,300 -32.84 50,532 -23.95 0.0066
2014-11-14 2014-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,413,968 -304,518 -17.72 66,442 -37.93 0.0090
2014-08-14 2014-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,718,486 53,700 3.23 107,044 -4.40 0.0143
2014-05-15 2014-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,664,786 0 0.00 111,974 27.87 0.0155
2014-02-13 2013-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,664,786 0 0.00 87,568 21.53 0.0124
2013-11-14 2013-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,664,786 443,700 36.34 72,052 57.69 0.0110
2013-09-24 2013-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 1,221,086 1,221,086 45,693 0.0075
2013-08-14 2013-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,221,086 45,693 0.0075
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.